Use of Eltrombopag to Improve Thrombocytopenia and Tranfusion Requirement in Anti-CD19 CAR-T Cell-Treated Patients
Authors:
- Maria-Eva Mingot-CastellanoMMMaria-Eva Mingot-Castellano
- Juan Luis Reguera-OrtegaJRJuan Luis Reguera-Ortega
- Denis Zafra TorresDTDenis Zafra Torres
- Rafael HernaniRHRafael Hernani
- Oriana Lopez-GodinoOLOriana Lopez-Godino
- Manuel GuerreiroMGManuel Guerreiro
- Blanca HerreroBHBlanca Herrero
- Lucia López-CorralLLLucia López-Corral
- Alejandro LunaALAlejandro Luna
- Lesli Gonzalez-PinedoLGLesli Gonzalez-Pinedo
- Anabelle Chinea-RodriguezACAnabelle Chinea-Rodriguez
- Ana Africa-MartínAAAna Africa-Martín
Open Access
- 28 August 2024
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (17) , 5117
Abstract
Background/Objectives: Immune effector cell-associated hematotoxicity (ICAHT) is a frequent adverse event after chimeric antigen receptor (CAR)-T cell therapy. Grade ≥ 3 thrombocytopenia occurs in around one-third of patients, and many of them become platelet transfusion-dependent. Eltrombopag is a thrombopoietin receptor agonist (TPO-RA) able to accelerate megakaryopoiesis, which has been used successfully in patients with bone marrow failure and immune thrombocytopenia (ITP). Its role in managing thrombocytopenia and other cytopenias in CAR-T cell-treated patients has been scarcely addressed. Our aim was to report the safety and efficacy of this approach in patients included in the Spanish Group for Hematopoietic Transplantation and Cellular Therapy (GETH-TC) registry. Methods: This is a retrospective, multicenter, observational study. Patients who developed platelet transfusion dependence subsequently to CAR-T cells and received eltrombopag to improve platelet counts were recruited in 10 Spanish hospitals. Results: Thirty-eight patients were enrolled and followed up for a median (interquartile range [IQR]) of 175 (99, 489) days since CAR-T cell infusion. At the moment eltrombopag was indicated, 18 patients had thrombocytopenia and another severe cytopenia, while 8 patients had severe pancytopenia. After 32 (14, 38) days on eltrombopag, 29 (76.3%) patients recovered platelet transfusion independence. The number of platelet units transfused correlated with the time needed to restore platelet counts higher than 20 × 109/L (Rho = 0.639, p < 0.001). Non-responders to eltrombopag required more platelet units (58 [29, 69] vs. 12 [6, 26] in responders, p = 0.002). Nineteen out of twenty-three (82.6%) patients recovered from severe neutropenia after 22 (11, 31) days on eltrombopag. Twenty-nine out of thirty-five (82.9%) patients recovered red blood cell (RBC) transfusion independence after 29 (17, 44) days. Seven patients recovered all cell lineages while on treatment. No thromboembolic events were reported. Only two transient toxicities (cholestasis, hyperbilirubinemia) were reported during eltrombopag treatment, none of which compelled permanent drug withdrawal. Conclusions: Eltrombopag could be safely used to manage thrombocytopenia and accelerate transfusion independence in CAR-T cell-treated patients.Keywords
All Related Versions
This publication has 50 references indexed in Scilit:
- Axicabtagene Ciloleucel versus Tisagenlecleucel for Relapsed or Refractory Large B Cell Lymphoma: A Systematic Review and Meta-AnalysisTransplantation and Cellular Therapy, 2024
- Optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonistsBlood Reviews, 2023
- Thrombopoietin receptor agonist for treating bone marrow aplasia following anti-CD19 CAR-T cells—single-center experienceAnnals of Hematology, 2022
- Current state and next-generation CAR-T cells in multiple myelomaBlood Reviews, 2022
- Engineered T Cells: CAR T Cell Therapy and BeyondCurrent Oncology Reports, 2022
- Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignanciesJournal of Allergy and Clinical Immunology, 2020
- Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell TransplantTransplantation and Cellular Therapy, 2019
- Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to ImmunomodulationDrugs, 2019
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- Persistent elevation of plasma thrombopoietin levels after treatment in severe aplastic anemiaExperimental Hematology, 2018